TW201726152A - Probiotic embedding particle capable of providing efficacies of body constitution adjustment, digestive functionality maintenance, gut microbiota variation, and low manufacturing cost - Google Patents

Probiotic embedding particle capable of providing efficacies of body constitution adjustment, digestive functionality maintenance, gut microbiota variation, and low manufacturing cost Download PDF

Info

Publication number
TW201726152A
TW201726152A TW105102832A TW105102832A TW201726152A TW 201726152 A TW201726152 A TW 201726152A TW 105102832 A TW105102832 A TW 105102832A TW 105102832 A TW105102832 A TW 105102832A TW 201726152 A TW201726152 A TW 201726152A
Authority
TW
Taiwan
Prior art keywords
probiotic
embedded
bacteria
group
producing
Prior art date
Application number
TW105102832A
Other languages
Chinese (zh)
Other versions
TWI587863B (en
Inventor
Chin-Chu Chen
Sheng-Chieh Hsu
Shu-Hsing Yeh
Shin-Wei Lin
Yen-Po Chen
Original Assignee
Grape King Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Grape King Inc filed Critical Grape King Inc
Priority to TW105102832A priority Critical patent/TWI587863B/en
Application granted granted Critical
Publication of TWI587863B publication Critical patent/TWI587863B/en
Publication of TW201726152A publication Critical patent/TW201726152A/en

Links

Landscapes

  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

A probiotic embedding particle and manufacturing method thereof are disclosed. The disclosed probiotic embedding particle comprises a probiotic sclerotium, a colloidal layer and a fungal hypha shell. The probiotic sclerotium is enclosed by the colloidal layer, and the colloidal layer is enclosed by the fungal hypha shell. The fungal hypha shell and the colloidal layer are functioned as an embedding structure that can effectively protect the probiotics. The fungal hypha shell comprises fungal nutrient substances which are capable of providing human body with health care effect when they are taken. Besides, with the structure of the fungal hypha shell, the stabilities of secondary processing and storage of the disclosed probiotic embedding particle can be increased. Further, the probiotic sclerotium can provide efficacies of body constitution adjustment, digestive functionality maintenance and gut microbiota variation, and the disclosed probiotic embedding particle can have a low manufacturing cost.

Description

一種益生菌包埋顆粒及其製造方法Probiotic bacteria embedded granule and preparation method thereof

本發明有關一種益生菌包埋顆粒及其製造方法,尤指一種以真菌菌絲包埋益生菌之包埋顆粒及其製造方法。The invention relates to a probiotic bacteria embedded particle and a manufacturing method thereof, in particular to an embedding particle for embedding probiotic bacteria by a fungus hyphae and a manufacturing method thereof.

益生菌(Probiotics)泛指利用碳水化合物進行發酵,生產多量乳酸之細菌。益生菌係藉由附著在宿主的腸道上,而防止病原菌入侵,對宿主有正面效益。目前市面上常見的益生菌種類為乳酸菌和酵母菌,而益生菌的產品型態主要為液體、粉體或硬膠囊。其中,由於益生菌的產品型態將影響其功效的發揮,故在開發和生產時係扮演重要的一環。Probiotics generally refer to bacteria that use carbohydrates for fermentation to produce large amounts of lactic acid. Probiotics prevent the invasion of pathogens by attaching to the gut of the host and have positive benefits for the host. The probiotics commonly found on the market today are lactic acid bacteria and yeasts, while the probiotics are mainly liquid, powder or hard capsules. Among them, since the product type of probiotics will affect its efficacy, it plays an important part in development and production.

以乳酸菌為例,例如中華民國發明專利公告第587098號,揭示一種增進免疫能力之乳酸菌,包含刺激免疫性濃度之下列任一或多種生物性純培養物:鼠李糖乳桿菌HN001 CCRC 910107;鼠李糖乳桿菌HN067 CCRC 910108;乳酸雙歧桿菌(Bifidobacteriumlactis)HN019 CCRC 910110或嗜酸乳桿菌(Lactobacillus acidophilus)HN017 CCRC 910109,及生理上可接受的賦形劑或稀釋劑,其中該賦形劑或該稀釋劑為食品,而該食品為醱酵乳、優格、乳酪、乳製飲品或乳粉。或如中華民國發明專利公告第I451871號,揭示一種食品組合物,用以抑制發炎反應,包含:多株乳酸菌菌株,其包含唾液乳酸桿菌(Lactobacillus salivarius)AP-32菌株,寄存編號BCRC 910437、路乳酸桿菌(Lactobacillus reuteri)TE-33菌株,寄存編號BCRC 910441、嗜酸乳酸桿菌(Lactobacillus acidophilus)F-1菌株,寄存編號BCRC 910469及鼠李糖乳酸桿菌(Lactobacillus rhamnosus)CT-53菌株,寄存編號BCRC 910468,其中該些乳酸菌菌株具有胃酸、膽鹽及抑霉劑克黴唑(Clotrimazole)耐受性;以及生理上可接受的一賦形劑或一稀釋劑,其中該賦形劑或該稀釋劑為醱酵乳、優格、乳酪、乳製飲品乳粉、茶或咖啡。以上先前技術中,乳酸菌劑型係為未經包埋處理的液體、粉體,由於乳酸菌對於環境的酸鹼度很敏感,又人體的胃酸、膽汁有殺菌作用,未經包埋的乳酸菌進入人體後菌體易被破壞,而不能發揮應有的療效;其次,由於未經包埋,乳酸菌的安定性不足,易使活菌數降低,導致儲存期短,不耐久存。Taking lactic acid bacteria as an example, for example, Republic of China Invention Patent Publication No. 587098, discloses a lactic acid bacteria capable of improving immunity, comprising any one or more of the following biologically pure cultures stimulating an immunological concentration: Lactobacillus rhamnosus HN001 CCRC 910107; Lactobacillus licheniformis HN067 CCRC 910108; Bifidobacterium lactis HN019 CCRC 910110 or Lactobacillus acidophilus HN017 CCRC 910109, and a physiologically acceptable excipient or diluent, wherein the excipient or The diluent is a food product, and the food is fermented milk, yogurt, cheese, dairy drink or milk powder. Or, as disclosed in the Chinese Patent Publication No. I451871, a food composition for inhibiting an inflammatory reaction, comprising: a plurality of strains of lactic acid bacteria comprising Lactobacillus salivarius AP-32 strain, accession number BCRC 910437, road Lactobacillus reuteri TE-33 strain, accession number BCRC 910441, Lactobacillus acidophilus F-1 strain, accession number BCRC 910469 and Lactobacillus rhamnosus CT-53 strain, registration number BCRC 910468, wherein the lactic acid bacteria strain has stomach acid, bile salt and mold inhibitor Clotrimazole tolerance; and a physiologically acceptable excipient or a diluent, wherein the excipient or the dilution The agent is fermented milk, yogurt, cheese, milk powder for dairy drinks, tea or coffee. In the above prior art, the lactic acid bacteria dosage form is a liquid or powder which is not embedded, because the lactic acid bacteria are sensitive to the pH of the environment, and the stomach acid and bile of the human body have a bactericidal effect, and the un-encapsulated lactic acid bacteria enter the human body and the bacteria body. It is easy to be destroyed, but it can not exert its proper curative effect. Secondly, due to the lack of embedding, the stability of lactic acid bacteria is insufficient, and the number of viable bacteria is easily reduced, resulting in short storage period and long-lasting survival.

有鑑於以上缺點,另有採膠囊包埋的乳酸菌,如中華民國發明專利公告第M384660號,揭示一種可抑制體內多餘脂肪生長之LS66膠囊組合結構,包含一本體、一個以上之LS66孢子乳酸菌以及一塗佈層,該本體包含一上膠囊與一下膠囊,而該上膠囊與該下膠囊結合後內部形成一容置空間,該LS66孢子乳酸菌係填設於上述容置空間內,該塗佈層塗佈於該本體內部表面,其中該塗佈層係為一活化劑。然而,經過硬膠囊包埋的乳酸菌,雖可保護菌體通過酸性的胃部環境,但硬膠囊於腸道不易溶解,使得釋出菌體的時機不穩定,且同樣有不耐久存的問題。In view of the above shortcomings, another lactic acid bacteria embedded in capsules, such as the Republic of China Invention Patent Publication No. M384660, discloses a LS66 capsule combination structure capable of inhibiting the growth of excess fat in the body, comprising a body, more than one LS66 spore lactic acid bacteria and one a coating layer, the body comprises an upper capsule and a lower capsule, and the upper capsule and the lower capsule are combined to form an accommodating space therein, and the LS66 spore lactic acid bacteria is filled in the accommodating space, and the coating layer is coated Deployed on the inner surface of the body, wherein the coating layer is an activator. However, the hard-capsule-embedded lactic acid bacteria can protect the cells from the acidic stomach environment, but the hard capsules are not easily dissolved in the intestinal tract, making the timing of releasing the cells unstable, and also having the problem of being inferior.

而除了以上液體、粉體和硬膠囊的產品型式之外,還有採用晶球作為包覆益生菌的材料者,然雖具有耐久存和耐胃酸、膽汁等優點,但其熱穩定性不佳,且於腸道中大約需六小時才能溶解釋出,此外,其價格昂貴。In addition to the above product types of liquids, powders and hard capsules, there are also crystal spheres used as materials for coating probiotics. However, although they have the advantages of durability and resistance to stomach acid and bile, their thermal stability is not good. And it takes about six hours to dissolve in the intestine, and in addition, it is expensive.

本發明的主要目的,在於解決習知液體和粉體益生菌產品,不耐胃酸、膽汁以及安定性不足和不耐久存的問題,而硬膠囊包埋的益生菌於腸道不易溶解及不耐久存的問題,晶球作包埋的益生菌價格昂貴的問題。The main object of the present invention is to solve the problems of conventional liquid and powder probiotic products, which are not resistant to stomach acid, bile, and lack of stability and long-lasting problems, while hard-encapsulated probiotics are not easily dissolved in the intestine and are not durable. The problem of survival is that the crystal ball is expensive for embedding probiotics.

為達以上目的,本發明提供一種益生菌包埋顆粒,包含一益生菌核;一膠狀物質層,包覆該益生菌核;以及一真菌菌絲殼層,包覆該膠狀物質層。To achieve the above object, the present invention provides a probiotic bacteria-embedded particle comprising a probiotic sclerotium; a gelatinous substance layer covering the probiotic sclerotium; and a fungal mycelium shell covering the gelatinous substance layer.

為達上述目的,本發明還提供一種益生菌包埋顆粒的製造方法,包含以下步驟:In order to achieve the above object, the present invention also provides a method for producing a probiotic-embedded particle, comprising the steps of:

提供一益生菌核;Providing a probiotic sclerotium;

以一第一風壓將一膠狀物質包覆於該益生菌核;Coating a gelatinous substance on the probiotic nucleus with a first wind pressure;

令該膠狀物質乾燥而形成一膠狀物質層;Drying the gelatinous substance to form a layer of a gelatinous substance;

以一第二風壓將一真菌菌絲包覆該膠狀物質層;以及Coating a fungal hyphae with the layer of the gelatinous substance by a second wind pressure;

令該真菌菌絲乾燥而形成一真菌菌絲殼層。The fungal hyphae are dried to form a fungal mycelium shell.

為達上述目的,本發明更提供一種益生菌包埋顆粒,係以前述方法得到。In order to achieve the above object, the present invention further provides a probiotic-embedded particle obtained by the aforementioned method.

由以上可知,本發明相較於習知技藝具有至少以下功效:From the above, the present invention has at least the following effects compared to the prior art:

一、 利用該真菌菌絲殼層和該膠狀物質層作為包埋結構,可有效保護益生菌,使該益生菌包埋顆粒的該益生菌核在胃酸環境中,保有其活性而不受破壞,而能順利到達小腸及大腸,且於鹼性腸道環境中較易溶解釋出。1. Using the fungal mycelial shell layer and the gelatinous substance layer as an embedding structure, the probiotic bacteria can be effectively protected, and the probiotic nucleus of the probiotic bacteria embedded in the stomach can retain its activity without being damaged in the stomach acid environment. It can reach the small intestine and large intestine smoothly, and is more soluble in the alkaline intestinal environment.

二、 其次,該真菌菌絲殼層係含有真菌營養物質,當人體食入後,可提供保健之效果,例如減緩過敏、降血壓、降血糖等。Secondly, the fungal mycelium shell contains fungal nutrients, which can provide health care effects when the body is ingested, such as slowing allergies, lowering blood pressure, lowering blood sugar, and the like.

三、 藉由該真菌菌絲殼層的結構,可增加該益生菌包埋顆粒二次加工之穩定性及儲存安定性。3. The stability of the secondary processing of the probiotic bacteria embedded particles and the storage stability can be increased by the structure of the fungal mycelial shell layer.

四、 該益生菌核具有調整體質、維持消化道機能及改變腸道菌相等功效,且該益生菌包埋顆粒的製造成本較低;此外,本發明之該益生菌包埋顆粒之生產成本較晶球包埋更為低廉,易於量產。4. The probiotic sclerotium has the functions of adjusting the constitution, maintaining the function of the digestive tract and changing the intestinal bacteria, and the manufacturing cost of the probiotic bacteria embedded particles is lower; in addition, the production cost of the probiotic bacteria embedded particles of the invention is higher The crystal ball is embedded in a lower cost and is easy to mass produce.

有關本發明的詳細說明及技術內容,現就配合圖式說明如下:The detailed description and technical content of the present invention will now be described as follows:

請參閱『圖1』和『圖2』所示,分別為本發明一實施例的立體結構示意圖以及『圖1』的A-A剖面示意圖,本發明提供一種益生菌包埋顆粒,包含一益生菌核10、一膠狀物質層20以及一真菌菌絲殼層30,該膠狀物質層20包覆該益生菌核10的一外表面,而該真菌菌絲殼層30包覆該膠狀物質層20的一外表面,於本實施例中,該益生菌核10、該膠狀物質層20和該真菌菌絲殼層30依序由內向外形成一多層同心球結構,而使該益生菌包埋顆粒呈一球狀,本文所稱的球狀包括表面光滑的完全球狀以及接近真球的多面體。Referring to FIG. 1 and FIG. 2, respectively, a schematic perspective view of an embodiment of the present invention and a cross-sectional view of AA of FIG. 1 are provided. The present invention provides a probiotic bacteria embedded particle comprising a probiotic sclerotium. 10. A gelatinous substance layer 20 and a fungal mycelium shell 30, the gelatinous substance layer 20 coating an outer surface of the probiotic sclerotium 10, and the fungal mycelium shell layer 30 coating the gelatinous substance layer An outer surface of 20, in the present embodiment, the probiotic sclerotium 10, the gelatinous substance layer 20 and the fungal mycelium shell layer 30 sequentially form a multi-layer concentric spherical structure from the inside to the outside, thereby making the probiotic bacteria The embedded particles are spherical, and the spherical shape referred to herein includes a completely spherical surface with a smooth surface and a polyhedron close to the true sphere.

如『圖2』所示,於本發明的一實施例中,該益生菌核10包括一菌穩定劑11以及複數個分散於該菌穩定劑11之中的益生菌12,該益生菌12包括複數個乳酸菌粉末,其中,該菌穩定劑11可為海藻糖、奶粉、聚糊精、味精、焦磷酸鹽、維他命、精氨酸或前述之組合,該益生菌12可為嗜酸乳桿菌(Lactobacillus acidophilus)、雷特氏B菌(Bifidobacteriumlactis)、屎腸球菌(Enterococcus faecium)、比菲德氏菌(Bifidobacteriumbifidum)或前述之組合。該膠狀物質層20的組成可為蟲膠(Shellac)、羥丙基甲基纖維素(Hydroxypropyl methylcellulose phthalate,簡稱HPMCP)、玉米蛋白(Zein)、明膠(Gelatine)、阿拉伯膠(Gum arabic)、膠原蛋白(Collagen)、海藻酸鈉(Alginic acid sodium)或前述之組合,該真菌菌絲殼層30的組成可為靈芝、樟芝、紅麴、冬蟲夏草、猴頭菇、蜜環菌、蟬花、姬松茸、蛹蟲草、舞茸、桑黃或前述之組合。As shown in FIG. 2, in an embodiment of the present invention, the probiotic sclerotia 10 includes a bacteria stabilizer 11 and a plurality of probiotics 12 dispersed in the bacteria stabilizer 11, and the probiotics 12 include a plurality of lactic acid bacteria powders, wherein the bacteria stabilizer 11 may be trehalose, milk powder, polydextrose, monosodium glutamate, pyrophosphate, vitamins, arginine or a combination thereof, and the probiotics 12 may be Lactobacillus acidophilus ( Lactobacillus acidophilus), Bifidobacterium lactis, Enterococcus faecium, Bifidobacterium bifidum or a combination of the foregoing. The composition of the gelatinous substance layer 20 may be Shellac, Hydroxypropylmethylcellulose phthalate (HPMCP), Zein, Gelatin, Gum arabic, Collagen, Alginic acid sodium or a combination thereof, the composition of the fungal mycelium shell 30 can be Ganoderma lucidum, Antrodia camphorata, Red peony, Cordyceps sinensis, Hericium erinaceus, Armillaria, and sassafras , Agaricus blazei, Cordyceps militaris, Maitake, mulberry or a combination of the foregoing.

本發明另提供一種益生菌包埋顆粒的製造方法,可利用一包埋設備配合低溫噴霧流動層技術進行,該方法包含以下步驟:The invention further provides a method for manufacturing a probiotic bacteria embedded particle, which can be carried out by using an embedding device and a low temperature spray flow layer technology, the method comprising the following steps:

步驟A:提供一益生菌核10,於本發明之一實施例,該益生菌核10包括一菌穩定劑11以及複數個分散於該菌穩定劑11之中的益生菌12,該菌穩定劑11和該益生菌12的組成如上所述。Step A: providing a probiotic nucleus 10, in one embodiment of the present invention, the probiotic nucleus 10 comprises a bacteria stabilizer 11 and a plurality of probiotics 12 dispersed in the bacteria stabilizer 11, the bacteria stabilizer The composition of 11 and the probiotic 12 is as described above.

步驟B:以一第一風壓將一膠狀物質包覆於該益生菌核10,於本發明之一實施例,該第一風壓介於0.5 kg/cm2 至2 kg/cm2 之間,且該益生菌核10係以一介於3rpm至30rpm之間的入料速度提供至產生該第一風壓的一噴嘴口。Step B: coating a gelatinous substance on the probiotic nucleus 10 with a first wind pressure. In an embodiment of the invention, the first wind pressure is between 0.5 kg/cm 2 and 2 kg/cm 2 . And the probiotic sclerotium 10 is supplied to a nozzle opening that produces the first wind pressure at a feed rate between 3 rpm and 30 rpm.

步驟C:令該膠狀物質乾燥而形成一膠狀物質層20,於本發明之一實施例,係於一介於3%至30%之間的相對溼度以及一介於20℃至55℃之間的溫度進行乾燥。Step C: drying the gelatinous substance to form a gelatinous substance layer 20, in an embodiment of the present invention, between a relative humidity of between 3% and 30% and a temperature between 20 ° C and 55 ° C The temperature is dried.

步驟D:以一第二風壓將一真菌菌絲包覆該膠狀物質層20,於本發明之一實施例,該第二風壓介於1 kg/cm2 至3 kg/cm2 之間。Step D: coating a fungal hyphae with the gelatinous substance layer 20 by a second wind pressure. In one embodiment of the present invention, the second wind pressure is between 1 kg/cm 2 and 3 kg/cm 2 . between.

步驟E:令該真菌菌絲乾燥而形成一真菌菌絲殼層30,於本發明之一實施例,係於一介於3%至30%之間的相對溼度以及一介於20℃至55℃之間的溫度進行乾燥。Step E: drying the fungal hyphae to form a fungal mycelium shell 30, in one embodiment of the invention, at a relative humidity of between 3% and 30% and a temperature between 20 ° C and 55 ° C The temperature between them is dried.

於本發明之一實施例,該益生菌核10的製備包括以下步驟:In an embodiment of the invention, the preparation of the probiotic nucleus 10 comprises the following steps:

步驟A-1:將一益生菌種於一發酵槽進行培養而得到該益生菌12,該發酵槽處於一介於32℃至40℃的溫度及一含有1 wt.%至5 wt.%之間的葡萄糖、0.1 wt.%至2 wt.%之間的蛋白腖及0.1 wt.%至3 wt.%之間的酵母萃取物的培養液。前述的濃度係指各培養原料佔該發酵槽之重量百分濃度。Step A-1: cultivating a probiotic strain in a fermenter to obtain the probiotic 12, the fermenter being at a temperature between 32 ° C and 40 ° C and containing between 1 wt.% and 5 wt.% a mixture of glucose, between 0.1 wt.% and 2 wt.% peptone and between 0.1 wt.% and 3 wt.% of the yeast extract. The aforementioned concentration means the concentration of each culture material in the weight percentage of the fermentation tank.

步驟A-2:於一介於10℃至30℃之間的溫度對該益生菌12進行一冷凍乾燥步驟。Step A-2: The probiotic 12 is subjected to a freeze-drying step at a temperature between 10 ° C and 30 ° C.

步驟A-3:於該益生菌12中加入該菌穩定劑11而得到該益生菌核10,該菌穩定劑11相對該益生菌核10具有一介於5 wt.%至15 wt.%之間的重量百分比。依照實際生產結果,該益生菌12的菌粉產量可達22 Kg以上,且菌數量達到1011 cfu/g以上。Step A-3: adding the bacteria stabilizer 11 to the probiotic 12 to obtain the probiotic sclerotium 10, the bacteria stabilizer 11 having a relative to the probiotic sclerotium 10 between 5 wt.% and 15 wt.% Percentage by weight. According to the actual production results, the probiotics 12 can produce more than 22 Kg of bacteria powder, and the number of bacteria reaches 10 11 cfu/g or more.

為進一步驗證本發明益生菌包埋顆粒之功效,請參閱以下依據本發明所進行之測試,此僅為舉例說明之用,並非用於限制本發明之範圍。以下測試包括不同噴霧條件對益生菌的安定性測試、不同乾燥溫度對益生菌的安定性測試、益生菌的水分含量和水活性測試以及誘導動物免疫活性之測試。In order to further verify the efficacy of the probiotic-embedded granules of the present invention, reference is made to the following tests conducted in accordance with the present invention, which are for illustrative purposes only and are not intended to limit the scope of the invention. The following tests included stability testing of probiotics for different spray conditions, stability testing of probiotics at different drying temperatures, moisture content and water activity testing of probiotics, and testing for induction of animal immune activity.

益生菌安定性測試Probiotic stability test -- 不同噴霧條件的影響Effect of different spray conditions

本測試包括三組比較組和實驗組,比較組1和實驗組1採用嗜酸乳桿菌(Lactobacillus acidophilus),比較組2和實驗組2採用屎腸球菌(Enterococcus faecium),比較組3和實驗組3採用雷特氏B菌(Bifidobacteriumlactis),包埋製程採取低溫噴霧流動層技術,以噴霧時間和噴霧濃度為變數。比較組包括了未經包埋的益生菌以及僅以噴霧技術包埋膠狀物質層的益生菌,而沒有包埋真菌菌絲殼層,噴霧的膠狀物質濃度為20 wt.%,其餘為溶劑,噴霧時間分別為30min、45min、60min。實驗組中,包埋膠狀物質層的噴霧濃度亦為20 wt.%,而包埋真菌菌絲殼層時,噴霧的真菌菌絲濃度分別為10 wt.%、15 wt.%、20 wt.%、25 wt.% ,其餘為溶劑,各組的噴霧時間分別為30min、45min、60min,完成後量測初始的益生菌數量以及1個月、2個月、3個月後的益生菌數量變化。表1、表2和表3分別顯示比較組1和實驗組1、比較組2和實驗組2、比較組3和實驗組3在不同條件下的益生菌數量。另補充說明,實驗組3僅有部分數據資料。 表1 比較組1和實驗組1的益生菌數量 表2 比較組2和實驗組2的益生菌數量 表3 比較組3和實驗組3的益生菌數量 The test consisted of three groups of comparison and experimental groups. Comparison group 1 and experiment group 1 used Lactobacillus acidophilus, comparison group 2 and experimental group 2 used Enterococcus faecium, comparison group 3 and experimental group. 3 Using Bifidobacterium lactis, the embedding process adopts low-temperature spray flow layer technology, with the spray time and spray concentration as variables. The comparison group consisted of unembedded probiotics and probiotics embedding the gelatinous material layer only by spray technique, without embedding the fungal mycelium shell, the concentration of the gelatinous substance sprayed was 20 wt.%, and the rest was The solvent and spray time were 30 min, 45 min, and 60 min, respectively. In the experimental group, the spray concentration of the embedded gelatinous substance layer was also 20 wt.%, and when the fungal mycelium shell was embedded, the sprayed fungal hyphae concentrations were 10 wt.%, 15 wt.%, 20 wt, respectively. .%, 25 wt.%, the rest are solvents. The spray time of each group is 30min, 45min, 60min respectively. After the completion, the initial probiotics and the probiotics after 1 month, 2 months and 3 months are measured. The quantity changes. Table 1, Table 2, and Table 3 show the number of probiotics in Comparative Group 1 and Experimental Group 1, Comparative Group 2, and Experimental Group 2, Comparative Group 3, and Experimental Group 3, respectively, under different conditions. In addition, the experimental group 3 has only partial data. Table 1 Comparison of Probiotics in Group 1 and Experimental Group 1 Table 2 Comparison of Probiotics in Group 2 and Experimental Group 2 Table 3 Comparison of probiotics in group 3 and experiment group 3

由以上可知,未經包埋或僅包埋膠狀物質層的益生菌,在3個月後的存活率顯著減少,甚至低於1%,可見本發明之包埋顆粒結構,確實能有效保護益生菌的活性並提高安定性;另一方面,不同的噴霧時間會影響益生菌的安定性,若噴霧時間太長,在儀器中反覆拋灑,會使益生菌受損而影響其存活率。It can be seen from the above that the survival rate of the probiotics without embedding or embedding the gel-like substance layer is significantly reduced after 3 months, even less than 1%, and the embedded particle structure of the present invention can be effectively protected. Probiotic activity and stability; on the other hand, different spray times will affect the stability of probiotics. If the spray time is too long, it will be thrown in the instrument, which will damage the probiotics and affect their survival rate.

益生菌安定性測試Probiotic stability test -- 不同乾燥溫度的影響Effect of different drying temperatures

本測試係針對根據前述益生菌安定性測試中最佳結果者,進一步觀察不同乾燥溫度對益生菌安定性的影響,其中,實驗組1選擇噴霧時間為30分鐘,噴霧濃度為15 wt.%,並命名為實驗組1-1;實驗組2選擇噴霧時間為30分鐘,噴霧濃度為10 wt.%,並命名為實驗組2-1;實驗組3選擇噴霧時間為30分鐘,噴霧濃度為20 wt.%,並命名為實驗組3-1。乾燥溫度則分別為40℃、50℃、60℃,表4顯示經過不同乾燥溫度後,實驗組1-1、實驗組2-1和實驗組3-1的益生菌數量如表4所示,由下表可知,乾燥溫度為40℃時的結果最佳。 表4 實驗組1-1、實驗組2-1和實驗組3-1的益生菌數量 This test is to further observe the effect of different drying temperatures on the stability of probiotics according to the best results in the aforementioned probiotic stability test. Among them, the experimental group 1 selects the spraying time as 30 minutes and the spray concentration is 15 wt.%. It was named as experimental group 1-1; experimental group 2 chose spray time of 30 minutes, spray concentration was 10 wt.%, and was named experimental group 2-1; experimental group 3 chose spray time of 30 minutes, spray concentration was 20 Wt.%, and named experimental group 3-1. The drying temperatures were 40 ° C, 50 ° C, and 60 ° C, respectively. Table 4 shows that the number of probiotics in the experimental group 1-1, the experimental group 2-1, and the experimental group 3-1 after different drying temperatures is shown in Table 4. As can be seen from the table below, the results were best when the drying temperature was 40 °C. Table 4 Number of probiotics in experimental group 1-1, experimental group 2-1 and experimental group 3-1

益生菌安定性測試Probiotic stability test -- 水分含量和水活性Moisture content and water activity

水分含量測試的步驟如下:The steps for moisture content testing are as follows:

步驟F-1:取3g之本發明益生菌包埋顆粒,並裝於樣品皿中。Step F-1: 3 g of the probiotic bacteria embedded particles of the present invention were taken and placed in a sample dish.

步驟F-2:打開樣品皿的蓋子並放置於烘箱於105℃烘乾4小時,使益生菌之水分蒸散,接著在烘箱中將蓋子蓋上再取出樣品皿。Step F-2: The lid of the sample dish was opened and placed in an oven at 105 ° C for 4 hours to evaporate the moisture of the probiotic bacteria, and then the lid was covered in an oven and the sample dish was taken out.

步驟F-3:將樣品皿置於密閉容器中並將乾燥劑放入密閉容器中,待益生菌包埋顆粒的溫度與室溫取得平衡後,將益生菌包埋顆粒取出秤重。Step F-3: The sample dish is placed in a closed container and the desiccant is placed in a closed container. After the temperature of the probiotic bacteria embedded particles is balanced with the room temperature, the probiotic bacteria embedded particles are taken out and weighed.

步驟F-4:秤重後,將樣品皿放置於烘箱在105℃烘乾1小時,再將樣品皿置於該密閉容器中回溫後取出秤重。Step F-4: After weighing, the sample dish is placed in an oven and dried at 105 ° C for 1 hour, and then the sample dish is placed in the closed container to be warmed up, and the weight is taken out.

步驟F-5:重覆進行步驟F-4:直到益生菌包埋顆粒的重量不再改變,並依照下式計算水分含量:Step F-5: Repeat step F-4 until the weight of the probiotic-embedded particles does not change, and calculate the moisture content according to the following formula:

水分含量=(乾燥前重-乾燥後重)/乾燥後重×100%。Moisture content = (heavy before drying - heavy after drying) / weight after drying × 100%.

本測試的結果顯示,益生菌包埋顆粒之水分含量皆係低於8%以下,顯示本發明之益生菌包埋顆粒具有優良的耐儲存性。The results of the test showed that the moisture content of the probiotic embedded particles was less than 8%, indicating that the probiotic embedded particles of the present invention have excellent storage resistance.

水活性的測試則是使用水活性分析儀分析2g之本發明之益生菌包埋顆粒,結果顯示水活性皆低於0.1以下,顯示本發明之益生菌包埋顆粒可改善細菌或黴菌腐敗之問題。The water activity test is to analyze 2 g of the probiotic embedded particles of the present invention using a water activity analyzer, and the results show that the water activity is less than 0.1, indicating that the probiotic embedded particles of the present invention can improve the bacterial or mold spoilage problem. .

誘導動物免疫活性之測試Test for inducing animal immune activity

本測試係比較本發明之益生菌包埋顆粒和未經包埋的益生菌對於誘導動物免疫活性的效果。本測試係以小鼠作為實驗對象,實驗組係以本發明之益生菌包埋顆粒餵食小鼠30天,比較組則是以未經真菌菌絲包埋的益生菌餵食小鼠30天,對照組則是未餵食益生菌。餵食結束後,將小鼠的脾臟細胞以裂殖素處理,裂殖素為刀豆素A (Concanavalin A,簡稱Con A)以及脂多糖(Lipopolysaccharide,簡稱LPS)。結果顯示,於Con A的刺激下,實驗組相較於對照組(無餵食)的淋巴細胞增生(P<0.01)比比較組相較於對照組(無餵食)的淋巴細胞增生(P<0.1)更多;另一方面,於LPS的刺激下,實驗組亦可增加淋巴細胞增生(P<0.1),結果如表5所示。 表5 對照組、比較組、實驗組的淋巴細胞數量 This test compares the effects of the probiotic embedded particles of the present invention and the unembedded probiotics on the induction of animal immune activity. In this test, mice were used as experimental subjects. The experimental group was fed with the probiotic bacteria embedded particles of the present invention for 30 days, and the comparison group was fed with probiotic bacteria without fungal hyphae for 30 days. The group is not fed probiotics. After the feeding, the spleen cells of the mice were treated with phlegm, which was Concanavalin A (Con A) and Lipopolysaccharide (LPS). The results showed that under the stimulation of Con A, the lymphocyte proliferation (P<0.01) of the experimental group compared with the control group (no feeding) was higher than that of the control group (no feeding) (P<0.1). On the other hand, under the stimulation of LPS, the experimental group also increased lymphocyte proliferation (P < 0.1), and the results are shown in Table 5. Table 5 Number of lymphocytes in the control group, comparison group, and experimental group

由以上可知,本發明之益生菌包埋顆粒經生物攝食後,代謝出真菌多醣體,其對免疫調節活性有其效益。From the above, it can be seen that the probiotic bacteria embedded particles of the present invention metabolize the fungal polysaccharide after biological feeding, which has an effect on the immunomodulatory activity.

綜上所述,本發明利用該真菌菌絲殼層和該膠狀物質層作為包埋結構,可有效保護益生菌,使該益生菌包埋顆粒的該益生菌核在胃酸環境中,保有其活性而不受破壞,而能順利到達小腸及大腸,且於鹼性腸道環境中較易溶解釋出;其次,該真菌菌絲殼層係含有真菌營養物質,當人體食入後,可提供保健之效果,例如減緩過敏、降血壓、降血糖等;藉由該真菌菌絲殼層的結構,可增加該益生菌包埋顆粒二次加工之穩定性及儲存安定性;該益生菌核具有調整體質、維持消化道機能及改變腸道菌相等功效,且該益生菌包埋顆粒的製造成本較低;此外,本發明益生菌包埋顆粒之生產成本較晶球包埋更為低廉,易於量產。In summary, the present invention utilizes the fungal mycelium shell layer and the gelatinous substance layer as an embedding structure, which can effectively protect the probiotic bacteria, and the probiotic nucleus of the probiotic bacteria embedded in the stomach acid environment, retaining the probiotic bacterium Active without damage, can reach the small intestine and large intestine smoothly, and is more easily dissolved in the alkaline intestinal environment; secondly, the fungal mycelium shell contains fungal nutrients, which can be provided when the human body ingests The effect of health care, such as slowing allergies, lowering blood pressure, lowering blood sugar, etc.; by the structure of the fungal mycelial shell layer, the stability and storage stability of the secondary processing of the probiotic bacteria embedded particles can be increased; the probiotic sclerotia has Adjusting the constitution, maintaining the function of the digestive tract and changing the equivalent efficacy of the intestinal bacteria, and the manufacturing cost of the probiotic bacteria embedded particles is low; in addition, the production cost of the probiotic bacteria embedded particles of the invention is lower than that of the crystal ball embedding, and is easy to be Mass production.

以上已將本發明做一詳細說明,惟以上所述者,僅爲本發明的一較佳實施例而已,當不能限定本發明實施的範圍。即凡依本發明申請範圍所作的均等變化與修飾等,皆應仍屬本發明的專利涵蓋範圍內。The present invention has been described in detail above, but the foregoing is only a preferred embodiment of the present invention, and is not intended to limit the scope of the invention. That is, the equivalent changes and modifications made by the scope of the present application should remain within the scope of the patent of the present invention.

10‧‧‧益生菌核
11‧‧‧菌穩定劑
12‧‧‧益生菌
20‧‧‧膠狀物質層
30‧‧‧真菌菌絲殼層
10‧‧‧Probiotic sclerotia
11‧‧·bacteria stabilizer
12‧‧‧Probiotics
20‧‧‧Colloidal layer
30‧‧‧Fungi mycelium shell

『圖1』,為本發明一實施例的立體結構示意圖。 『圖2』,為『圖1』的A-A剖面示意圖。FIG. 1 is a schematic perspective view of an embodiment of the present invention. "Fig. 2" is a schematic view of the A-A section of Fig. 1.

10‧‧‧益生菌核 10‧‧‧Probiotic sclerotia

11‧‧‧菌穩定劑 11‧‧·bacteria stabilizer

12‧‧‧益生菌 12‧‧‧Probiotics

20‧‧‧膠狀物質層 20‧‧‧Colloidal layer

30‧‧‧真菌菌絲殼層 30‧‧‧Fungi mycelium shell

Claims (22)

一種益生菌包埋顆粒,包含: 一益生菌核; 一膠狀物質層,包覆該益生菌核;以及 一真菌菌絲殼層,包覆該膠狀物質層。A probiotic embedded particle comprising: a probiotic sclerotium; a layer of a gelatinous substance covering the probiotic sclerotium; and a fungal mycelium shell covering the layer of the gelatinous substance. 如申請專利範圍第1項所述的益生菌包埋顆粒,其中該益生菌核包括一菌穩定劑以及一分散於該菌穩定劑之中的益生菌。The probiotic granule according to claim 1, wherein the probiotic sclerotium comprises a bacteria stabilizer and a probiotic dispersed in the bacteria stabilizer. 如申請專利範圍第2項所述的益生菌包埋顆粒,其中該菌穩定劑擇自於海藻糖、奶粉、聚糊精、味精、焦磷酸鹽、維他命及精氨酸所組成的群組。The probiotic-embedded particles according to claim 2, wherein the bacteria stabilizer is selected from the group consisting of trehalose, milk powder, polydextrin, monosodium glutamate, pyrophosphate, vitamins and arginine. 如申請專利範圍第2項所述的益生菌包埋顆粒,其中該益生菌包括複數個益生菌粉末。The probiotic-embedded granule of claim 2, wherein the probiotic comprises a plurality of probiotic powders. 如申請專利範圍第2項所述的益生菌包埋顆粒,其中該益生菌擇自於嗜酸乳桿菌、屎腸球菌、雷特氏B菌及比菲德氏菌所組成的群組。The probiotic bacteria-embedded particles according to claim 2, wherein the probiotics are selected from the group consisting of Lactobacillus acidophilus, Enterococcus faecium, B. glutinosa and Bifidobacterium. 如申請專利範圍第1項所述的益生菌包埋顆粒,其中該膠狀物質層的組成擇自於蟲膠、羥丙基甲基纖維素、玉米蛋白、明膠、阿拉伯膠、膠原蛋白及海藻酸鈉所組成的群組。The probiotic-embedded particles according to claim 1, wherein the composition of the gelatinous substance layer is selected from shellac, hydroxypropylmethylcellulose, zein, gelatin, gum arabic, collagen and seaweed. A group consisting of sodium. 如申請專利範圍第1項所述的益生菌包埋顆粒,其中該真菌菌絲殼層擇自於靈芝、樟芝、紅麴、冬蟲夏草、猴頭菇、蜜環菌、蟬花、姬松茸、蛹蟲草、舞茸及桑黃所組成的群組。The probiotic bacteria embedded particles according to claim 1, wherein the fungal mycelium shell layer is selected from the group consisting of ganoderma lucidum, anthocyanin, red peony, cordyceps sinensis, hericium erinaceus, honey fungus, sassafras, jasmine, A group of Cordyceps, Maitake and Sanghuang. 如申請專利範圍第1項所述的益生菌包埋顆粒,其中該益生菌核、該膠狀物質層以及該真菌菌絲殼層依序由內向外形成一多層同心球結構。The probiotic bacteria-embedded particles according to claim 1, wherein the probiotic sclerotium, the gelatinous substance layer and the fungal mycelial shell layer sequentially form a multi-layer concentric spherical structure from the inside to the outside. 一種益生菌包埋顆粒的製造方法,包含以下步驟: 提供一益生菌核; 以一第一風壓將一膠狀物質包覆於該益生菌核; 令該膠狀物質乾燥而形成一膠狀物質層; 以一第二風壓將一真菌菌絲包覆該膠狀物質層;以及 令該真菌菌絲乾燥而形成一真菌菌絲殼層。A method for producing a probiotic-embedded particle comprises the steps of: providing a probiotic sclerotium; coating a gelatinous substance on the probiotic sclerotium at a first wind pressure; drying the gelatinous substance to form a gel a layer of material; coating a fungal hyphae with the layer of the gelatinous substance at a second wind pressure; and drying the fungal hyphae to form a fungal mycelium shell. 如申請專利範圍第9項所述的益生菌包埋顆粒的製造方法,其中該第一風壓介於0.5 kg/cm2 至2 kg/cm2 之間。The method for producing a probiotic-embedded particle according to claim 9, wherein the first wind pressure is between 0.5 kg/cm 2 and 2 kg/cm 2 . 如申請專利範圍第9項所述的益生菌包埋顆粒的製造方法,其中該第二風壓介於1 kg/cm2 至3 kg/cm2 之間。The method for producing a probiotic-embedded particle according to claim 9, wherein the second wind pressure is between 1 kg/cm 2 and 3 kg/cm 2 . 如申請專利範圍第9項所述的益生菌包埋顆粒的製造方法,其中乾燥該膠狀物質係於一介於3%至30%之間的相對溼度以及一介於20℃至55℃之間的溫度進行。The method for producing a probiotic-embedded particle according to claim 9, wherein the gel-like substance is dried at a relative humidity of between 3% and 30% and between 20 ° C and 55 ° C. The temperature is carried out. 如申請專利範圍第9項所述的益生菌包埋顆粒的製造方法,其中乾燥該真菌菌絲係於一介於3%至30%之間的相對溼度以及一介於20℃至55℃之間的溫度進行。The method for producing a probiotic-embedded particle according to claim 9, wherein the fungal hyphae are dried at a relative humidity of between 3% and 30% and a temperature between 20 ° C and 55 ° C. The temperature is carried out. 如申請專利範圍第9項所述的益生菌包埋顆粒的製造方法,其中該益生菌核係以一介於3rpm至30rpm之間的入料速度提供至產生該第一風壓的一噴嘴口。The method for producing a probiotic-embedded granule according to claim 9, wherein the probiotic nucleus is supplied to a nozzle opening for generating the first wind pressure at a feed rate of between 3 rpm and 30 rpm. 如申請專利範圍第9項所述的益生菌包埋顆粒的製造方法,其中該益生菌核的製備包括以下步驟: 將一益生菌種於一發酵槽進行培養而得到一益生菌,該發酵槽處於一介於32℃至40℃之間的溫度及一含有1 wt.%至5 wt.%之間的葡萄糖、0.1 wt.%至2 wt.%之間的蛋白腖及0.1 wt.%至3 wt.%之間的酵母萃取物的培養液; 於一介於10℃至30℃之間的溫度對該益生菌進行一冷凍乾燥步驟;以及 於該益生菌中加入一菌穩定劑而得到該益生菌核,該穩定劑相對該益生菌核具有一介於5 wt.%至15 wt.%之間的重量百分比。The method for producing a probiotic granule according to claim 9, wherein the preparation of the probiotic nucleus comprises the steps of: cultivating a probiotic strain in a fermentation tank to obtain a probiotic, the fermenter At a temperature between 32 ° C and 40 ° C and between 1 wt.% and 5 wt.% glucose, between 0.1 wt.% and 2 wt.% peptone and 0.1 wt.% to 3 wt a culture solution of yeast extract between .%; a freeze-drying step of the probiotic bacteria at a temperature between 10 ° C and 30 ° C; and adding a bacteria stabilizer to the probiotic to obtain the probiotic bacteria The nucleus has a weight percentage between 5 wt.% and 15 wt.% relative to the probiotic sclerotium. 如申請專利範圍第9項所述的益生菌包埋顆粒的製造方法,其中該益生菌核包括一菌穩定劑以及一分散於該菌穩定劑之中的益生菌。The method for producing a probiotic-embedded granule according to claim 9, wherein the probiotic sclerotium comprises a bacteriostatic agent and a probiotic bacterium dispersed in the bacterium stabilizer. 如申請專利範圍第16項所述的益生菌包埋顆粒的製造方法,其中該菌穩定劑擇自於海藻糖、奶粉、聚糊精、味精、焦磷酸鹽、維他命及精氨酸所組成的群組。The method for producing a probiotic-embedded granule according to claim 16, wherein the bacterium stabilizer is selected from the group consisting of trehalose, milk powder, polydextrin, monosodium glutamate, pyrophosphate, vitamins and arginine. Group. 如申請專利範圍第16項所述的益生菌包埋顆粒的製造方法,其中該益生菌包括複數個益生菌粉末。The method for producing a probiotic-embedded granule according to claim 16, wherein the probiotic comprises a plurality of probiotic powders. 如申請專利範圍第16項所述的益生菌包埋顆粒的製造方法,其中該益生菌擇自於嗜酸乳桿菌、屎腸球菌、雷特氏B菌及比菲德氏菌所組成的群組。The method for producing a probiotic-embedded particle according to claim 16, wherein the probiotic is selected from the group consisting of Lactobacillus acidophilus, Enterococcus faecium, Leit B bacteria, and Bifidobacterium group. 如申請專利範圍第9項所述的益生菌包埋顆粒的製造方法,其中該膠狀物質層的組成擇自於蟲膠、羥丙基甲基纖維素、玉米蛋白、明膠、阿拉伯膠、膠原蛋白及海藻酸鈉所組成的群組。The method for producing a probiotic-embedded particle according to claim 9, wherein the composition of the gelatinous substance layer is selected from shellac, hydroxypropylmethylcellulose, zein, gelatin, gum arabic, collagen. A group of proteins and sodium alginate. 如申請專利範圍第9項所述的益生菌包埋顆粒的製造方法,其中該真菌菌絲殼層擇自於靈芝、樟芝、紅麴、冬蟲夏草、猴頭菇、蜜環菌、蟬花、姬松茸、蛹蟲草、舞茸及桑黃所組成的群組。The method for producing a probiotic-embedded granule according to claim 9, wherein the fungal mycelium shell is selected from the group consisting of ganoderma lucidum, anthraquinone, red peony, cordyceps sinensis, hericium erinaceus, honey fungus, sassafras, A group consisting of Agaricus blazei, Cordyceps militaris, Maitake and mulberry. 一種益生菌包埋顆粒,係以申請專利範圍第9項的方法得到。A probiotic-embedded granule obtained by the method of claim 9 of the patent application.
TW105102832A 2016-01-29 2016-01-29 A probiotic entrapping particle TWI587863B (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
TW105102832A TWI587863B (en) 2016-01-29 2016-01-29 A probiotic entrapping particle

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
TW105102832A TWI587863B (en) 2016-01-29 2016-01-29 A probiotic entrapping particle

Publications (2)

Publication Number Publication Date
TWI587863B TWI587863B (en) 2017-06-21
TW201726152A true TW201726152A (en) 2017-08-01

Family

ID=59687865

Family Applications (1)

Application Number Title Priority Date Filing Date
TW105102832A TWI587863B (en) 2016-01-29 2016-01-29 A probiotic entrapping particle

Country Status (1)

Country Link
TW (1) TWI587863B (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021109879A1 (en) 2019-12-06 2021-06-10 倪健伟 Composition having wholesome personalized intestinal flora diversity function and application

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111436612A (en) * 2020-04-22 2020-07-24 绵阳市润土农业科技开发有限公司 In-vivo enzyme, preparation method thereof and application of in-vivo enzyme in inhibiting novel viruses

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110070334A1 (en) * 2009-09-20 2011-03-24 Nagendra Rangavajla Probiotic Stabilization
TW201129694A (en) * 2010-02-26 2011-09-01 Univ Hungkuang Multi-coating macro-granule structure comprising probiotics and manufacturing method thereof
TWM479761U (en) * 2014-02-26 2014-06-11 New Bellus Entpr Co Ltd Lactic acid bacterium embedding structure
TWM487084U (en) * 2014-03-28 2014-10-01 Pilot Biotechnology Co Ltd Microcapsules structure capsulating lactic acid bacteria

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021109879A1 (en) 2019-12-06 2021-06-10 倪健伟 Composition having wholesome personalized intestinal flora diversity function and application

Also Published As

Publication number Publication date
TWI587863B (en) 2017-06-21

Similar Documents

Publication Publication Date Title
Silva et al. Symbiotic microencapsulation to enhance Lactobacillus acidophilus survival
Islam et al. Microencapsulation of live probiotic bacteria
CN110025638B (en) Chitosan-sodium carboxymethyl cellulose layer-by-layer self-assembly probiotic microcapsule and preparation thereof
Prakash et al. Artificial cell therapy: New strategies for the therapeutic delivery of live bacteria
CN111011867B (en) Probiotic embedded particle and preparation method thereof
CN106434438A (en) Preparation method and application of high-stress-resistant probiotics
CN110367542B (en) Probiotic microcapsule slowly released in intestinal tract and preparation method thereof
CN112335884A (en) Novel probiotic microsphere and preparation method thereof
TWI587863B (en) A probiotic entrapping particle
CN113230284B (en) Synbiotic microencapsulated preparation based on multi-dimensional crosslinking and preparation method and application thereof
Zhou et al. Combinedly increased viability of Lactiplantibacillus plantarum grx16 by co‐encapsulation of cryoprotectants and porous starch within calcium alginate capsules
CN113424965A (en) Microecological preparation more suitable for yellow population
CN107881133A (en) A kind of high-activity bifidobacterium powder vacuum drying production technology and application
TWM393167U (en) Multi-coating macro-granule structure comprising probiotics
Zhou et al. Evaluation of Streptococcus thermophilus IFFI 6038 microcapsules prepared using an ultra-fine particle processing system
TWM487084U (en) Microcapsules structure capsulating lactic acid bacteria
CN114343186A (en) Probiotics capsule for promoting enterokinesia
CN114747769A (en) Probiotic product and preparation method thereof
WO2022266840A1 (en) Probiotic microcapsule, and preparation method therefor and use thereof
CN114009644A (en) Stomach-nourishing probiotic solid beverage resistant to gastric acid and preparation method thereof
CN206214443U (en) Embedding particle capable of improving nerve growth factor lactic acid bacteria by embedding hericium erinaceus hypha
TWM526399U (en) Embedding particle with Armillaria mellea mycelia used for embedding Lactic acid bacteria
CN115624180B (en) Probiotics microcapsule containing osteopontin and preparation method thereof
TWM526396U (en) Embedding particle with Antrodia camphorata protein used for embedding lactic acid bacteria
TW202019395A (en) Lactic acid bacteria crystal composition capable of promoting intestinal stem cell proliferation, antiviral, anti-inflammatory and anti-allergic effects and preparation method thereof.